Clin Ther. 2013 Nov;35(11):1728-32. \[[PMC free article: PMC3888154](/pmc/articles/PMC3888154/)\] \[[PubMed: 24145043](https://pubmed.ncbi.nlm.nih.gov/24145043)\] 4. Choi NG, DiNitto DM, Marti CN, Choi BY. Adults who misuse opioids: Substance abuse treatment use and perceived treatment need. Subst Abus. 2019;40(2):247-255. \[[PubMed: 30810503](https://pubmed.ncbi.nlm.nih.gov/30810503)\] 5. Emery MA, Eitan S. Members of the same pharmacological family are not alike: Different opioids, different consequences, hope for the opioid crisis? Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 08;92:428-449. \[[PubMed: 30790677](https://pubmed.ncbi.nlm.nih.gov/30790677)\] 6. Park K, Otte A. Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities. Annu Rev Biomed Eng. 2019 Jun 04;21:61-84. \[[PubMed: 30786212](https://pubmed.ncbi.nlm.nih.gov/30786212)\] 7. Rollman JE, Heyward J, Olson L, Lurie P, Sharfstein J, Alexander GC. Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products. JAMA. 2019 Feb 19;321(7):676-685. \[[PMC free article: PMC6439622](/pmc/articles/PMC6439622/)\] \[[PubMed: 30778596](https://pubmed.ncbi.nlm.nih.gov/30778596)\] 8. Reisman RM, Shenoy PJ, Atherly AJ, Flowers CR. Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy. Subst Abuse. 2009;3:41-51. \[[PMC free article: PMC3865068](/pmc/articles/PMC3865068/)\] \[[PubMed: 24357929](https://pubmed.ncbi.nlm.nih.gov/24357929)\] 9. LaForge KS, Yuferov V, Kreek MJ. Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur J Pharmacol. 2000 Dec 27;410(2-3):249-268. \[[PubMed: 11134674](https://pubmed.ncbi.nlm.nih.gov/11134674)\] 10. Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev. 2005 Mar;57(1):1-26. \[[PubMed: 15734726](https://pubmed.ncbi.nlm.nih.gov/15734726)\] 11. Webster LR. Risk Factors for Opioid-Use Disorder and Overdose. Anesth Analg. 2017 Nov;125(5):1741-1748. \[[PubMed: 29049118](https://pubmed.ncbi.nlm.nih.gov/29049118)\] 12. Park TW, Lin LA, Hosanagar A, Kogowski A, Paige K, Bohnert AS. Understanding Risk Factors for Opioid Overdose in Clinical Populations to Inform Treatment and Policy. J Addict Med. 2016 Nov/Dec;10(6):369-381. \[[PubMed: 27525471](https://pubmed.ncbi.nlm.nih.gov/27525471)\] 13. Foglia R, Kline A, Cooperman NA. New and Emerging Opioid Overdose Risk Factors. Curr Addict Rep. 2021;8(2):319-329. \[[PMC free article: PMC8061156](/pmc/articles/PMC8061156/)\] \[[PubMed: 33907663](https://pubmed.ncbi.nlm.nih.gov/33907663)\] 14. Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S. A "krokodil" emerges from the murky waters of addiction. Abuse trends of an old drug. Life Sci. 2014 May 02;102(2):81-7. \[[PubMed: 24650492](https://pubmed.ncbi.nlm.nih.gov/24650492)\] 15. Stein C. Opioid Receptors. Annu Rev Med. 2016;67:433-51. \[[PubMed: 26332001](https://pubmed.ncbi.nlm.nih.gov/26332001)\] 16. Millan MJ, Cz≈Çonkowski A, Lipkowski A, Herz A. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action. J Pharmacol Exp Ther. 1989 Oct;251(1):342-50. \[[PubMed: 2571723](https://pubmed.ncbi.nlm.nih.gov/2571723)\] 17. Priest KC, Gorfinkel L, Klimas J, Jones AA, Fairbairn N, McCarty D. Comparing Canadian and United States opioid agonist therapy policies. Int J Drug Policy. 2019 Dec;74:257-265. \[[PMC